MeSH tree: N05.715.360.575.575.800.474
Late-breaking results from the Phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate noninferiority to paclitaxel/carboplatin followed by letrozole (PC/L) for progression-free survival (PFS) ...
Apr 13, 2026
0
2
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone lymphoma, according to a recent clinical trial published in The Lancet. Marginal zone lymphoma ...
Mar 4, 2026
0
6
Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or no negative impact on survival among people living with multiple myeloma, according to new international ...
Mar 2, 2026
0
9
Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy compared with surgery ...
Feb 27, 2026
0
7
A study by investigators from Mass General Brigham Cancer Institute evaluates the efficacy and safety of proton therapy for patients with lower grade gliomas (LGGs). The single-arm prospective phase 2 trial results demonstrated ...
Feb 11, 2026
0
9
New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival ...
Feb 9, 2026
0
15
For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine therapies leads to improved ...
Feb 2, 2026
0
6
Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease progression than patients receiving treatment later in the day. The findings, published as part of a randomized ...
Feb 2, 2026
0
39
For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields significantly ...
Jan 22, 2026
0
14
Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the immunotherapy nivolumab (Opdivo) instead of the immunotherapy brentuximab vedotin (brand name Adcetris) along ...
Jan 13, 2026
0
12
